Literature DB >> 33882210

Platform Trials - Beware the Noncomparable Control Group.

Lori E Dodd1, Boris Freidlin2, Edward L Korn2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33882210     DOI: 10.1056/NEJMc2102446

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  21 in total

1.  Awake prone positioning for COVID-19 acute hypoxaemic respiratory failure: a randomised, controlled, multinational, open-label meta-trial.

Authors:  Stephan Ehrmann; Jie Li; Miguel Ibarra-Estrada; Yonatan Perez; Ivan Pavlov; Bairbre McNicholas; Oriol Roca; Sara Mirza; David Vines; Roxana Garcia-Salcido; Guadalupe Aguirre-Avalos; Matthew W Trump; Mai-Anh Nay; Jean Dellamonica; Saad Nseir; Idrees Mogri; David Cosgrave; Dev Jayaraman; Joan R Masclans; John G Laffey; Elsa Tavernier
Journal:  Lancet Respir Med       Date:  2021-08-20       Impact factor: 30.700

2.  PICO Questions and DELPHI Methodology for the Management of Venous Thromboembolism Associated with COVID-19.

Authors:  Antoni Riera-Mestre; Luis Jara-Palomares; Ramón Lecumberri; Javier Trujillo-Santos; Enric Grau; Angeles Blanco-Molina; Ana Piera Carbonell; Sonia Jiménez; Manuel Frías Vargas; Mari Paz Fuset; Sergi Bellmunt-Montoya; Manuel Monreal; David Jiménez
Journal:  Viruses       Date:  2021-10-22       Impact factor: 5.048

3.  Use of anti-spike monoclonal antibodies in kidney transplant recipients with COVID-19: Efficacy, ethnic and racial disparities.

Authors:  Elizabeth J Klein; Anna Hardesty; Kendra Vieira; Dimitrios Farmakiotis
Journal:  Am J Transplant       Date:  2021-09-30       Impact factor: 9.369

4.  Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial.

Authors:  Jozefien Declercq; Karel F A Van Damme; Elisabeth De Leeuw; Bastiaan Maes; Cedric Bosteels; Simon J Tavernier; Stefanie De Buyser; Roos Colman; Maya Hites; Gil Verschelden; Tom Fivez; Filip Moerman; Ingel K Demedts; Nicolas Dauby; Nicolas De Schryver; Elke Govaerts; Stefaan J Vandecasteele; Johan Van Laethem; Sebastien Anguille; Jeroen van der Hilst; Benoit Misset; Hans Slabbynck; Xavier Wittebole; Fabienne Liénart; Catherine Legrand; Marc Buyse; Dieter Stevens; Fre Bauters; Leen J M Seys; Helena Aegerter; Ursula Smole; Victor Bosteels; Levi Hoste; Leslie Naesens; Filomeen Haerynck; Linos Vandekerckhove; Pieter Depuydt; Eva van Braeckel; Sylvie Rottey; Isabelle Peene; Catherine Van Der Straeten; Frank Hulstaert; Bart N Lambrecht
Journal:  Lancet Respir Med       Date:  2021-10-29       Impact factor: 30.700

Review 5.  Randomised clinical trials in critical care: past, present and future.

Authors:  Anders Granholm; Waleed Alhazzani; Lennie P G Derde; Derek C Angus; Fernando G Zampieri; Naomi E Hammond; Rob Mac Sweeney; Sheila N Myatra; Elie Azoulay; Kathryn Rowan; Paul J Young; Anders Perner; Morten Hylander Møller
Journal:  Intensive Care Med       Date:  2021-12-02       Impact factor: 41.787

6.  Early Use of Sarilumab in Patients Hospitalized with COVID-19 Pneumonia and Features of Systemic Inflammation: the SARICOR Randomized Clinical Trial.

Authors:  Nicolás Merchante; Sheila Cárcel; José Carlos Garrido-Gracia; Marta Trigo-Rodríguez; María Ángeles Esteban Moreno; Rafael León-López; Reinaldo Espíndola-Gómez; Eduardo Aguilar Alonso; David Vinuesa García; Alberto Romero-Palacios; Inés Pérez-Camacho; Belén Gutiérrez-Gutiérrez; Francisco Javier Martínez-Marcos; Concepción Fernández-Roldán; Pedro María Martínez Pérez-Crespo; Alexandra Aceituno Caño; Eva León; Juan E Corzo; Carmen de la Fuente; Julián Torre-Cisneros
Journal:  Antimicrob Agents Chemother       Date:  2021-12-13       Impact factor: 5.191

Review 7.  Distinctive features of severe SARS-CoV-2 pneumonia.

Authors:  G R Scott Budinger; Alexander V Misharin; Karen M Ridge; Benjamin D Singer; Richard G Wunderink
Journal:  J Clin Invest       Date:  2021-07-15       Impact factor: 19.456

8.  Tocilizumab for the treatment of non-critical COVID-19 pneumonia: an overview of the rationale and clinical evidence to date.

Authors:  Grace Kenny; Patrick W G Mallon
Journal:  Expert Rev Clin Pharmacol       Date:  2021-07-26       Impact factor: 5.045

9.  PRINCIPLE: a community-based COVID-19 platform trial.

Authors:  John Macleod; John Norrie
Journal:  Lancet Respir Med       Date:  2021-07-28       Impact factor: 30.700

10.  Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial.

Authors:  Yaseen M Arabi; Anthony C Gordon; Lennie P G Derde; Alistair D Nichol; Srinivas Murthy; Farah Al Beidh; Djillali Annane; Lolowa Al Swaidan; Abi Beane; Richard Beasley; Lindsay R Berry; Zahra Bhimani; Marc J M Bonten; Charlotte A Bradbury; Frank M Brunkhorst; Meredith Buxton; Adrian Buzgau; Allen Cheng; Menno De Jong; Michelle A Detry; Eamon J Duffy; Lise J Estcourt; Mark Fitzgerald; Rob Fowler; Timothy D Girard; Ewan C Goligher; Herman Goossens; Rashan Haniffa; Alisa M Higgins; Thomas E Hills; Christopher M Horvat; David T Huang; Andrew J King; Francois Lamontagne; Patrick R Lawler; Roger Lewis; Kelsey Linstrum; Edward Litton; Elizabeth Lorenzi; Salim Malakouti; Daniel F McAuley; Anna McGlothlin; Shay Mcguinness; Bryan J McVerry; Stephanie K Montgomery; Susan C Morpeth; Paul R Mouncey; Katrina Orr; Rachael Parke; Jane C Parker; Asad E Patanwala; Kathryn M Rowan; Marlene S Santos; Christina T Saunders; Christopher W Seymour; Manu Shankar-Hari; Steven Y C Tong; Alexis F Turgeon; Anne M Turner; Frank Leo Van de Veerdonk; Ryan Zarychanski; Cameron Green; Scott Berry; John C Marshall; Colin McArthur; Derek C Angus; Steven A Webb
Journal:  Intensive Care Med       Date:  2021-07-12       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.